Protonix IV

See also: Generic Protonix

Protonix IV is a brand name of pantoprazole, approved by the FDA in the following formulation(s):

PROTONIX IV (pantoprazole sodium - injectable; iv (infusion))

• 
  Manufacturer: WYETH PHARMS INC
  
  Approval date: March 22, 2001
  
  Strength(s): EQ 40MG BASE/VIAL ^[RLD]

Has a generic version of Protonix IV been approved?

No. There is currently no therapeutically equivalent version of Protonix IV available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Protonix IV. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Freeze-dried pantoprazole preparation and pantoprazole injection
  Patent 6,780,881
  Issued: August 24, 2004
  Inventor(s): Rudolf; Linder & Rango; Dietrich
  Assignee(s): Altana Pharma AG
  Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
  
  Patent expiration dates:
  
  
  • November 17, 2021
    
    ✓ 
    Drug product
  
  
  
  • May 17, 2022
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Freeze-dried pantoprazole preparation and pantoprazole injection
  Patent 7,351,723
  Issued: April 1, 2008
  Inventor(s): Linder; Rudolf & Dietrich; Rango
  Assignee(s): Nycomed GmbH
  Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
  
  Patent expiration dates:
  
  
  • November 17, 2021
    
    ✓ 
    Drug product
  
  
  
  • May 17, 2022
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Protonix I.V. Consumer Information (Wolters Kluwer)
• Protonix IV Advanced Consumer Information (Micromedex)
• Pantoprazole Consumer Information (Wolters Kluwer)
• Pantoprazole Delayed-Release Tablets Consumer Information (Wolters Kluwer)
• Pantoprazole Suspension Consumer Information (Wolters Kluwer)
• Pantoprazole Consumer Information (Cerner Multum)
• Pantoprazole Advanced Consumer Information (Micromedex)
• Pantoprazole Intravenous Advanced Consumer Information (Micromedex)
• Pantoprazole Sodium AHFS DI Monographs (ASHP)